0194: Prospective analysis of plasma cholesterol and triglycerides in patients (pts) with chronic phase (CP)-chronic myeloid leukemia (CML) during treatment with the 2nd generation tyrosine kinase inhibitor

MLA

Jean Francois Gautier, et al. “0194: Prospective Analysis of Plasma Cholesterol and Triglycerides in Patients (Pts) with Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) during Treatment with the 2nd Generation Tyrosine Kinase Inhibitor.” Archives of Cardiovascular Diseases Supplements, vol. 7, no. 1, Jan. 2015. EBSCOhost, https://doi.org/10.1016/s1878-6480(15)71713-1.

APA

Jean Francois Gautier, Tristan Mirault, Emmanuel Messas, Delphine Rea, & Hervé Dombret. (2015). 0194: Prospective analysis of plasma cholesterol and triglycerides in patients (pts) with chronic phase (CP)-chronic myeloid leukemia (CML) during treatment with the 2nd generation tyrosine kinase inhibitor. Archives of Cardiovascular Diseases Supplements, 7(1). https://doi.org/10.1016/s1878-6480(15)71713-1

Chicago

Jean Francois Gautier, Tristan Mirault, Emmanuel Messas, Delphine Rea, and Hervé Dombret. 2015. “0194: Prospective Analysis of Plasma Cholesterol and Triglycerides in Patients (Pts) with Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) during Treatment with the 2nd Generation Tyrosine Kinase Inhibitor.” Archives of Cardiovascular Diseases Supplements 7 (1). doi:10.1016/s1878-6480(15)71713-1.